<DOC>
	<DOC>NCT01539473</DOC>
	<brief_summary>Phase 1 study to determine the effect of oral TR-701 FA on SBP response when administered with tyramine</brief_summary>
	<brief_title>A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge</brief_title>
	<detailed_description>This is a Phase 1, randomized, double-blind, placebo-controlled, 2-way crossover study to determine the effect of 200 mg oral TR-701 FA on SBP response when administered with tyramine in healthy adult male and female volunteers.</detailed_description>
	<mesh_term>Torezolid phosphate</mesh_term>
	<mesh_term>Tyramine</mesh_term>
	<criteria>Male or female subjects between 18 to 45 years of age, inclusive Body mass index between 19 kg/m2 and 31 kg/m2, inclusive Healthy subjects with no clinically significant abnormalities identified by a detailed medical history, Systolic blood pressure &gt;130 mmHg or &lt;90 mmHg measured after 10 minutes in the supine position at Screening or at admission to the study center Heart rate &gt;90 bpm or &lt;45 bpm measured after 10 minutes in the supine position Electrocardiogram (ECG) finding of QTc interval &gt;500 msec, or other clinically significant ECG abnormality at the Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>